Guizhou Bailing Group Pharmaceutical Co., Ltd. (SHE:002424)
China · Delayed Price · Currency is CNY 4.240
-0.130 (-2.97%)
Nov 13, 2026, 3:04 PM CST
SHE:002424 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Revenue | 2,347 | 3,037 | 3,811 | 4,256 | 3,530 | 3,080 |
Other Revenue | 11.87 | 11.87 | 14.42 | 7.31 | 10.4 | 31.08 |
| 2,359 | 3,049 | 3,825 | 4,263 | 3,540 | 3,111 | |
Revenue Growth | -25.16% | -20.30% | -10.27% | 20.42% | 13.79% | 0.75% |
Cost of Revenue | 1,507 | 1,658 | 1,660 | 1,953 | 1,438 | 1,271 |
Gross Profit | 851.87 | 1,391 | 2,166 | 2,310 | 2,103 | 1,840 |
Selling, General & Admin | 740.93 | 1,224 | 2,083 | 2,560 | 1,747 | 1,481 |
Research & Development | 5.07 | 17.96 | 23.1 | 42.04 | 22.4 | 30.43 |
Other Operating Expenses | 72.96 | 38.19 | 39.89 | 40.29 | 49.21 | 39.14 |
Operating Expenses | 828.72 | 1,283 | 2,146 | 2,713 | 1,879 | 1,617 |
Operating Income | 23.15 | 108 | 19.62 | -402.34 | 223.43 | 222.85 |
Interest Expense | -52.5 | -61.78 | -85.83 | -91.58 | -101.66 | -116.26 |
Interest & Investment Income | 1.2 | 0.63 | 24.93 | 6.54 | 31.18 | 3.74 |
Currency Exchange Gain (Loss) | - | - | - | 0 | 0 | 0.06 |
Other Non Operating Income (Expenses) | 6.87 | -11.66 | 34.69 | -16.83 | -22.87 | -33.05 |
EBT Excluding Unusual Items | -26.45 | 35.19 | -6.59 | -504.22 | 130.08 | 77.33 |
Gain (Loss) on Sale of Investments | -31.5 | -31.5 | -35.07 | -4.3 | 9.64 | 58.53 |
Gain (Loss) on Sale of Assets | 18.03 | 18.12 | -0.14 | 1.14 | -0.3 | -0.47 |
Asset Writedown | 8.53 | -5.58 | -0.12 | 0.15 | -0.09 | -0.92 |
Other Unusual Items | 5.81 | 24.23 | 108.83 | 14.17 | 19.72 | 7.16 |
Pretax Income | -25.58 | 40.47 | 66.91 | -493.07 | 159.06 | 141.63 |
Income Tax Expense | 106.02 | 143.6 | 30.14 | -80.61 | 22.81 | 32.1 |
Earnings From Continuing Operations | -131.59 | -103.12 | 36.77 | -412.46 | 136.25 | 109.53 |
Minority Interest in Earnings | 2.35 | -1.24 | -3.14 | -2.05 | 2.23 | 8.95 |
Net Income | -129.24 | -104.37 | 33.62 | -414.51 | 138.47 | 118.48 |
Net Income to Common | -129.24 | -104.37 | 33.62 | -414.51 | 138.47 | 118.48 |
Net Income Growth | - | - | - | - | 16.87% | -22.24% |
Shares Outstanding (Basic) | 1,437 | 1,305 | 1,681 | 1,382 | 1,385 | 1,481 |
Shares Outstanding (Diluted) | 1,437 | 1,305 | 1,681 | 1,382 | 1,385 | 1,481 |
Shares Change | -12.57% | -22.40% | 21.67% | -0.22% | -6.50% | 6.92% |
EPS (Basic) | -0.09 | -0.08 | 0.02 | -0.30 | 0.10 | 0.08 |
EPS (Diluted) | -0.09 | -0.08 | 0.02 | -0.30 | 0.10 | 0.08 |
EPS Growth | - | - | - | - | 25.00% | -27.27% |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Free Cash Flow | 116.12 | 623.47 | -33 | 21.65 | 433.7 | -100.81 |
Free Cash Flow Per Share | 0.08 | 0.48 | -0.02 | 0.02 | 0.31 | -0.07 |
Gross Margin | 36.12% | 45.63% | 56.61% | 54.19% | 59.39% | 59.13% |
Operating Margin | 0.98% | 3.54% | 0.51% | -9.44% | 6.31% | 7.16% |
Profit Margin | -5.48% | -3.42% | 0.88% | -9.72% | 3.91% | 3.81% |
Free Cash Flow Margin | 4.92% | 20.45% | -0.86% | 0.51% | 12.25% | -3.24% |
EBITDA | 143.03 | 221.86 | 125.45 | -297.53 | 326.77 | 318.05 |
EBITDA Margin | 6.06% | 7.28% | 3.28% | -6.98% | 9.23% | 10.22% |
D&A For EBITDA | 119.88 | 113.85 | 105.82 | 104.82 | 103.35 | 95.2 |
EBIT | 23.15 | 108 | 19.62 | -402.34 | 223.43 | 222.85 |
EBIT Margin | 0.98% | 3.54% | 0.51% | -9.44% | 6.31% | 7.16% |
Effective Tax Rate | - | 354.80% | 45.05% | - | 14.34% | 22.66% |
Revenue as Reported | 2,359 | 3,049 | 3,825 | 4,263 | 3,540 | 3,111 |